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The concept that the renin–angiotensin system (RAS) plays
a major role in the development, progression and clinical
manifestations of heart failure has become widely accepted
over the past several decades. The importance of the
angiotensin (Ang) II Type 1 (AT1) receptor in mediating
most of the pathophysiologic effects of Ang II has also been
well established. Nonetheless, finding a role for the angio-
tensin receptor blockers (ARBs) in the treatment of heart
failure has not been an easy task, nor is it by any means
complete at this time. Much of the difficulty is related to the
fact that by the time the ARBs became available in clinical
practice, a substantial body of evidence demonstrating that
the angiotensin-converting enzyme inhibitors (ACEIs) im-
proved the natural history of patients with heart failure had
already been accumulated (1). Based on the consistency of
beneficial effects that were seen in clinical trials encompass-
ing a broad spectrum of patients ranging from individuals
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with asymptomatic left ventricular dysfunction to those with
advanced symptoms, the ACEIs emerged as a cornerstone
of therapy for heart failure (2). The ACEIs also have been
shown to reduce mortality and progression to heart failure in
myocardial infarction survivors (3,4). More recently, the
results of the Heart Outcomes Prevention Evaluation
(HOPE) study indicate that their clinical benefits (includ-
ing prevention of heart failure) extend to patients with
evidence of (or risk factors for) atherosclerotic vascular
disease (5). So persuasive is the evidence of the efficacy of
the ACEIs that their prescription is used as a quality
indicator for the management of heart failure.
Thus, studies evaluating the effects of ARBs have had to
be designed with the recognition that ACEIs are considered
to be effective in improving the clinical course in virtually all
stages of heart failure resulting from systolic dysfunction.
This has posed a problem because a major effect of both
classes of agents is to limit the interaction of Ang II with the
AT1 receptor, the ACEIs by blocking Ang II generation
and the ARBs by competing with the peptide for receptor
occupancy. Thus, despite important pharmacologic differ-
ences between these classes of drugs, including the ability of
the ARBs to directly block the effects of Ang II regardless
of how it is generated (thereby affording protection against
Ang II that is generated within tissue through nonangiotensin-
converting enzyme pathways using enzymes such as chy-
mase [6]), the ARBs failed to demonstrate superiority to the
ACEIs in improving the clinical course of heart failure
patients (7), nor do they reduce the incidence of worrisome
increases in renal function tests in the heart failure popula-
tion compared with the ACEIs (8). However, there is
evidence that the ARBs are clearly better tolerated by
patients than the ACEIs in treating both heart failure and
hypertension (7–10). When added to standard therapy (that
included ACEIs in most patients) in the Valsartan Heart
Failure Trial (Val-HeFT), an ARB was shown to have
essentially no effect on mortality, although there was a
significant improvement in morbidity mainly because of a
reduction in heart failure hospitalizations (11). Even this
piece of good news for the ARBs, however, has been
tempered by the observation that patients who were receiv-
ing beta-blockers in addition to an ACEI in Val-HeFT
experienced an increased risk for morbidity and mortality
when the ARB was introduced. This finding has raised the
possibility that the combination of an ACEI, ARB and
beta-blocker may have unexpected deleterious consequences
in the heart failure population.
With the ACEIs so well established as a therapy for heart
failure, an important issue that has faced clinicians is
whether or not ARBs by themselves improve survival and
reduce morbidity in heart failure patients. Thus, the post-
hoc analysis of the patients not receiving an ACEI who were
included in Val-HeFT that is reported in this issue of the
Journal is a welcome and interesting addition to the medical
literature (12). In Val-HeFT, 366 patients (7% of the study
population) were not, for one reason or another, on an
ACEI at the time that they were randomized to either
valsartan or placebo. The investigators found that the
addition of the ARB to these patients was associated with
significant reductions in the mortality and combined mor-
bidity and mortality end points that were used in the main
trial. In contrast, only the latter end point was significantly
improved by the addition of valsartan in the entire 5,010-
patient Val-HeFT study population. Moreover, the 33%
reduction in mortality with the ARB in patients not
receiving an ACEI was of the magnitude that one might
have expected to see with an ACEI in this population, and
the substantial 53% risk reduction for heart failure hospi-
talization is very relevant clinically. Changes in secondary
end points, though small in magnitude, were generally in
the favor of a beneficial effect of the ARB. These findings
provide evidence of physiologic benefits that help support
and explain the clinical ones that were seen in this analysis.
Also encouraging was the fact that there was no evidence of
a reversal of these favorable effects in the patient group that
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was receiving a beta-blocking agent when the ARB was
added.
These results, although encouraging, need to be inter-
preted with caution. As wisely pointed out by the authors,
the results of this post-hoc analysis do not carry nearly the
same weight as would the results of a clinical trial that was
specifically designed and adequately powered to assess the
effects of the ARBs on clinical end points in a population
not receiving an ACEI. The number of patients included in
the present subgroup analysis was relatively small and
several characteristics of the selected population were sig-
nificantly different from the general study population, in-
cluding the fact that the patients not receiving an ACEI
when the trial began were older, more likely to be female,
had more advanced symptoms and had a greater likelihood
of having an ischemic etiology of their heart failure. They
also had higher average ejection fraction and systolic blood
pressure rates than did the rest of the study population.
Other more subtle and/or not reported differences between
the non-ACEI subgroup and the other patients that could
have influenced the outcome may also have been present. At
the least, these concerns limit the generalizability of the
findings in the present report to the broader universe of
heart failure patients.
Even more important is the fact that considerable past
experience with heart failure trials that were not adequately
powered has taught us the lesson that the beneficial effects
that such trials purport to show may simply be the result of
the play of chance. The danger in accepting results from
underpowered trials (or subgroups of larger studies) no
matter how sizable the effects (or what p value was reached)
has become apparent when the results of adequately pow-
ered trials demonstrated either lack of benefit or even
harmful effects of a promising new therapy (7,8,13,14).
Fortunately, more definitive information about the efficacy
of ARBs in ACEI-intolerant patients will be available when
the results of one of the arms of the CHARM study that is
specifically designed and adequately powered to assess this
issue is reported (15).
Finally, small subgroup analyses such as this one derived
from Val-HeFT offer little or no insight into the character-
istics of the patients that might be more (or less) likely to
benefit from treatment with an ARB, nor are we able to
discern the optimal dose of valsartan for treating patients
with heart failure. Additional questions regarding the effi-
cacy of ARBs other than valsartan in this population also
remain unanswered. Given the differences between the
various ARBs in the characteristics of their antagonism of
Ang II at the AT1 receptor site (16) and in other properties
of the individual molecules (17,18) that could be relevant in
treating heart failure patients, this question is of more than
passing interest.
Although the ACEIs have been shown to benefit patients
with heart failure, there is information that up to 20% of
patients may not be receiving them because of real or
perceived side effects (19,20). What then is the best ap-
proach to treating these patients with the evidence that is
currently available? First, it would be important to deter-
mine if the reason for excluding the ACEI is due to actual
side effects such as cough or angioedema. If it is not, efforts
should be made to re-initiate therapy with an ACEI. For
patients who cannot be started or maintained on an ACEI;
however, the use of an ARB is warranted. This is based on
the known role of Ang II in the pathogenesis of heart failure
and it is supported by the present results of the Val-HeFT
subgroup analysis of patients not receiving an ACEI. As
with the ACEIs, a beta-blocker should also be given unless
there is a specific contraindication to the administration of
drugs in this class.
These recommendations, of course, await the results of
CHARM to substantiate, refute or further modify them. It
is also worth considering at this moment in time what the
current recommendations might be if it had been the ARBs
rather than the ACEIs that were the first class of drugs
introduced to interfere with the RAS and to treat heart
failure. What then might we be saying today about the role
of the ACEIs in the management of patients with heart
failure and what difficulties might there be in finding their
appropriate place in the therapeutic regimen?
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